Catheter Precision, Inc. filings document material events, operating results, shareholder votes, capital-structure matters, and governance disclosures for a NYSE American-listed company. The records include 8-K reports on financial results and business updates tied to the company’s electrophysiology products, including VIVO and LockeT, as well as strategic expansion activity.
VTAK’s proxy and current-report filings also cover stockholder approval matters, common-stock issuance proposals, convertible preferred stock series, promissory note amendments, royalty-right exchanges, related-party transaction disclosures, and other material agreements. These filings frame the company’s public reporting around medical device commercialization, financing arrangements, and corporate governance.
Catheter Precision, Inc. filed an amendment to its annual report mainly to expand disclosures on related-party transactions and director independence. The amendment does not change previously reported financial statements.
Key items include an oral employment arrangement with the CEO’s adult daughter, who serves as non-executive chief operating officer and received $165,000 in cash compensation for 2025 plus multiple option and warrant grants. The company also details several financing and restructuring transactions with entities controlled by Executive Chairman and Chief Executive Officer David A. Jenkins.
On December 31, 2025, the company exchanged royalty rights on its LockeT device held by Mr. Jenkins and FatBoy Capital, LP for 9,489.488 shares of Series J Convertible Preferred Stock, with a $1,000 stated value per share. The exchange eliminated approximately $2.7 million of related-party royalty payables, recognized $5.3 million as additional paid-in capital, and created a $2.6 million loss on debt extinguishment. The Series J Preferred Stock is convertible into 6,083,005 common shares at $1.56 per share if stockholders approve the underlying share issuance.
The company also extended maturity dates on related-party promissory notes totaling $1.5 million and issued 340,000 Series M warrants at a $1.56 exercise price to Mr. Jenkins and FatBoy, valued at about $509,000. Additional disclosures cover the transfer of non-operating PeriKard, LLC membership interests to Mr. Jenkins, formation of majority-owned subsidiaries Cardionomix, Inc. and KardioNav, Inc. with minority stakes granted to Mr. Jenkins and affiliates, and waiver of a 9.99% beneficial ownership limit to allow the Jenkins Family Charitable Institute to exercise 12,368 prefunded warrants. The board also reaffirms that three non-employee directors meet NYSE American independence standards and outlines committee compositions.
Catheter Precision, Inc. completed a private financing and issued new preferred stock that can convert into common shares, which may dilute existing holders over time. The company sold 3,470 shares of Series C-2 Convertible Preferred Stock at a stated value of $1,000 per share for aggregate gross proceeds of $3,470,000, primarily to fund working capital and general corporate purposes.
It also issued 11,028 shares of Series D Convertible Preferred Stock as part of the consideration for acquiring Fly Flyte, Inc. Both preferred series are initially convertible at set prices, with a floor price of $0.35 per share and anti-dilution adjustments, and include a beneficial ownership cap initially set at 4.99% that holders may increase to 9.99% with advance notice. Certificates of Designation filed in Delaware establish that these preferred shares rank senior to common stock in dividends and liquidation, reinforcing their priority but increasing potential dilution if converted.
Catheter Precision, Inc. reported the results of a Special Meeting of stockholders held on April 15, 2026. Of the 2,357,127 shares of common stock outstanding as of March 9, 2026, 1,165,698 shares were represented in person or by proxy, representing approximately 49.5% of shares entitled to vote.
Stockholders considered six proposals described in the company’s definitive proxy statement filed on March 23, 2026. The company disclosed detailed vote tallies for each proposal, including votes for, votes against, abstentions, and broker non-votes.
Catheter Precision, Inc. reported 2025 results showing revenue growth of 95% year over year but a GAAP net loss of $17.7M. After adding back non-cash items such as intangible asset impairment and debt extinguishment, the company reported a 2025 non-GAAP adjusted net loss of $7.8M.
For Q4 2025, GAAP net loss was $5.3M and non-GAAP adjusted net loss was $3.5M. Management highlighted progress in commercializing its VIVO and LockeT cardiac devices and, after year-end, completed the acquisition of Flyte, a regional air mobility company, creating two operating platforms in medical devices and aviation.
The company also disclosed risk factors, including that it does not have sufficient liquidity to fund operations through fiscal 2026 without additional financing or a strategic transaction, and outlined numerous operational, regulatory, and integration risks around its products and the Flyte expansion.
Catheter Precision, Inc. outlines its cardiac electrophysiology-focused business built around the VIVO 3D mapping system and LockeT vascular closure device, alongside new subsidiaries Cardionomix and KardioNav targeting heart failure and device-integrated mapping technologies. The company reports a going concern uncertainty, highlighting an accumulated deficit and reliance on external financing after raising approximately $4.9 million in 2025. As of March 20, 2026, it had 2,692,473 shares outstanding and a June 2025 public float valued at about $3.9 million. Management plans to grow by expanding VIVO indications, building clinical evidence for LockeT, leveraging international approvals, and selectively pursuing complementary technologies, but warns of significant regulatory, reimbursement, competition, and capital-raising risks.
Catheter Precision, Inc. reported that Chairman and CEO David A. Jenkins received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share, expire on March 26, 2036, and vest 100% 180 days after the grant date.
Catheter Precision, Inc. reported that its Chief Financial Officer, Philip J. Anderson, received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036.
The options were awarded as a compensation grant and vest 100% on the 180-day anniversary of the grant date. Following this grant, Anderson holds derivative securities representing rights to acquire 40,000 shares of Catheter Precision common stock through these options.
Catheter Precision, Inc. director Arno Andrew received a grant of stock options as part of his compensation. The award covers 40,000 options to buy common stock at an exercise price of $1.15 per share, expiring on March 26, 2036. The options vest 100% on the 180-day anniversary of the grant date, and following this grant he holds 40,000 derivative securities of this type directly.
Catheter Precision, Inc. director James Joseph Caruso received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036. According to the grant terms, the options vest 100% on the 180-day anniversary of the grant date.
Catheter Precision, Inc. director Martin J. Colombatto received a grant of stock options on Common Stock. The award covers 40,000 options with an exercise price of $1.15 per share, expiring on March 26, 2036. The options vest 100% on the 180-day anniversary of the grant date, and following this grant he holds 40,000 options directly.